ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Scopolamine: A Rapid Responding Antidepressant

Updated on July 1, 2015

Depression Treatment

Rapid Responding Antidepressant
Rapid Responding Antidepressant

Promising Research

If you have heard of Scopolamine at all, you have most likely heard of it being used for motion sickness and as a sedative. And if you are familiar with the use of antidepressants, you know it typically takes three to four weeks before any improvements in mood symptoms can be detected.

If you are a person with severe symptoms or are caring for a patient or a loved one with suicidal thoughts and behaviors, three to four weeks is a long time to wait. Sometimes several medication trials are necessary to find the medication(s) that work, since responses vary from person to person, and due to differences in how different antidepressants work. It can take months to achieve satisfactory relief of symptoms. Most people will have given up by then, and are even more hopeless about getting better than they were before.

There are an estimated 30-40 percent of depressed patients who do not respond at all to antidepressants. Half of the people in the United States who are diagnosed with depression, are not receiving treatment at all, according to a recent study.

Antidepressants have already played a significant role in relieving depressive symptoms that historically were considered untreatable. Before antidepressants, a person with depression was all too often housed in a mental institution, and sometimes treated with harsh, primitive treatments that were not successful in alleviating symptoms.

Current research efforts have been focused on finding new medications that work differently from the current ones, that might be effective for the 30-40% of patients who are not helped by current antidepressants, and that act more quickly than the current ones. A recent clinical trial confirmed results from earlier research, and showed that scopolamine could alleviate symptoms of depression within days. The study was small and additional studies will need to be done, but the findings suggest that a different class of medication has the potential to provide rapid treatment of depression.

Most antidepressant medications target serotonin, a neurotransmitter in the brain that is known to play a role in mood symptoms. There has been previous research that has suggested that other neurotransmitter systems play a role in depression, but serotonin has been considered to be more central in the development of depression. Scopolamine interacts with cell receptors for the neurotransmitter, acetylcholine.

The recent study was an attempt to repeat the results of an earlier study showing that scopolamine worked to relieve depressive symptoms quickly in patients with major depressive disorder or bipolar disorder. The recent study focused on people with major depressive disorder, and involved administering scopolamine or a placebo intravenously. Neither the patients nor the clinicians administering the medication knew who actually received the scopolamine.

The patients who received scopolamine reported positive effects by the time they returned for their second dose 3 to 5 days after their initial dose, and test scores measuring depressive symptoms declined 32-53% after three treatments. Some of the patients experienced complete remission of depressive symptoms. While it was a small study, 64% of participants achieved 50% reduction in symptoms by the end of the study.

Side effects of scopolamine include drowsiness, dry mouth, light headedness, and blurred vision. These symptoms typically resolve within hours. The antidepressant effects lasted weeks after the medication was no longer in the bloodstream. When used for motion sickness, the scopolamine is administered in smaller doses, which explains why the antidepressant effect hadn’t been noticed earlier. The study will need to be repeated in larger groups, and more practical ways to administer the medication, rather than intravenous, need to be developed. Additional research on exactly how the drug works and on developing new medications is needed. It will likely be several years before scopolamine will be developed and used as an antidepressant.

Depression is costly both to individuals and to society, and is painful. It is a leading cause of disability, and a significant risk factor for suicide – the 11th leading cause of death in the United States. The possibility of a rapid treatment will render hope to persons who are experiencing a disease that includes hopelessness as a symptom. The need for a rapid treatment for depression is an urgent one.

References

Drevets, W.C. and Furey, M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biological Psychiatry 67:432-8, 2010.

Furey, M.L. and Drevets, W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine. Archives of General Psychiatry 63:1121-1129, 2006.

Understanding Depression

Comments

    0 of 8192 characters used
    Post Comment

    • kimh039 profile imageAUTHOR

      Kim Harris 

      3 years ago

      Thank you MT:) I also wrote a hub on ketamine as another fast acting anti-depressant. I have been hearing a lot about that in the news recently and have thought about updating that hub. Your comments have encouraged me to do so. Thank you!

    • Minnetonka Twin profile image

      Linda Rogers 

      3 years ago from Minnesota

      I always love to read about research on updates on meds for depression, anxiety and other mental health issues. This drug sounds hopeful, especially since it can reduce depression quicker than the current meds that are used these days. As someone in the mental health field and someone who has dealt with depression and anxiety throughout her life, I thank you for the great information. Voted up, hit many buttons and sharing all over.

    • kimh039 profile imageAUTHOR

      Kim Harris 

      6 years ago

      thanks, healthwriterbob. (I like your name, btw) I hope so too. I think much more testing will need to be done on scopolamine and ketamine before it would be approved, but it's a start.....and, my, what impressive credentials you have:)

    • healthwriterbob profile image

      healthwriterbob 

      6 years ago from United States

      Hi kimh039,

      Very well-written hub. Hopefully, new studies will confirm the observation with intravenous scopolamine. Maybe an oral formulation with good efficacy is possible too. Voted up and useful.

    • kimh039 profile imageAUTHOR

      Kim Harris 

      7 years ago

      :

    • imatellmuva profile image

      imatellmuva 

      7 years ago from Somewhere in Baltimore

      kimh039, thank for the reply to my comment! Battling depression is no easy journey, and especially during the time it takes to get to that "Right Fit"!

      The close to your reply made my day, and brought tears of laughter to my eyes!! You're wickedly awesome!!!!

    • kimh039 profile imageAUTHOR

      Kim Harris 

      7 years ago

      Thank you imatellmuva. I think a lot of people can just "go to the doctor" - their PCP, and quickly find a med that is effective. Some people need to see a psychiatrist and a therapist for awhile to get better. A good fit is important, especially with the therapist; Although, I could see where a person with severe depression symptoms could try a thousand therapists and not ever find a good fit, because of the kind of thinking a person does with depression. If that's the case, I'd say just stick with one for awhile and start working with them. You should get some results in 6-8 session even if it's not a good fit. Your friend/loved one is lucky to have you for love and support. I'm going to follow you over to the hub on ketamine. If you're not there, I'ma tell muva!

    • imatellmuva profile image

      imatellmuva 

      7 years ago from Somewhere in Baltimore

      Very interesting, well written, and quite informative. I'm on my way to read the hub on ketamine. I am helping someone to deal with and manage depression. While depression can be managed, it can take great pains to find the right medication and/or combination of med/therapy for a long-term and successful outcome. Too often people say, go to the doctor, and it's not as cut and dry as that. Finding a doctor that IS helpful to YOU is what's key.

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      It's not being used yet, Bard - still being researched. You'll really love my newest hub on ketamine being researched as a rapid responding antidepressant as well. Thanks for stopping to read and comment, Bard of Ely.

    • Bard of Ely profile image

      Steve Andrews 

      8 years ago from Lisbon, Portugal

      Interesting hub, Kim! I know of this substance as an alkaloid that is found in several members of the nightshade family with poisonous but hallucinogenic properties. I have also heard that it has been used as a "truth serum." I was not aware it was used as an antidepressant too!

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      hmmm, you just made a good point Micky Dee. There are definitely some drawbacks to another instant feel good pill! I hope your struggles this morning challenge you to live up to your true Micky Dee throughout the day. I think you're wonderful. Thanks for stopping by.

    • Micky Dee profile image

      Micky Dee 

      8 years ago

      You got any on you? I could use some this morning! Thank you again Dear!

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      Thank you so much for your kind words and personal endorsement, highvoltagewriter. I'm glad you found the right medication, and thanks for pointing out the importance of finding a "good fit" for a therapist as well. That can sometimes take some time too!

    • Highvoltagewriter profile image

      William Benner 

      8 years ago from Savannah GA.

      great stuff for someone like my self who has dealt with depression most of my life. Over all it has greatly improved thanks to the right medication and the right therapist. Also for me, the break though came about when I turned my life over to God. Thank you for this great hub!

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      thanks v:) i was surprised to learn that 1/2 the people with depression don't get treatment!

    • valeriebelew profile image

      valeriebelew 

      8 years ago from Metro Atlanta, GA, USA

      Wonderful news, Kimh, as the length of time it takes for antidpressants to work is a major problem, and some have historically committed suicide waiting for them to take effect. Very good news, and very well written. thumbs up to you. (: v

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      ...and thank you billyaustin for your valuable feedback and ongoing support. I suspect it is the taboo, as well as the expense and the low priority that contributes to so many people not getting treatment.

    • kimh039 profile imageAUTHOR

      Kim Harris 

      8 years ago

      Thank you for your heart-felt comment saddlerider1. It is sad that people are still suffering depressive symptoms, when depression is so treatable.

    • billyaustindillon profile image

      billyaustindillon 

      8 years ago

      Kim a well researched hub about a most difficult subject. This is still a subject taboo to many - a big thumbs up also from me.

    • saddlerider1 profile image

      saddlerider1 

      8 years ago

      Kim this is a very informative hub and I thank you for sharing your knowledge. Depression has certainly become a widespread problem in societies around the world. So many people need not suffer. The advancement of medicines have suggested a turn for the better and it's medication as you've just described that are helping tremendously. I hope further cures are discovered for many of our generation. I give this hub a big up.

    working

    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, hubpages.com uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at: https://hubpages.com/privacy-policy#gdpr

    Show Details
    Necessary
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the googleapis.com or gstatic.com domains, for performance and efficiency reasons. (Privacy Policy)
    Features
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Marketing
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Statistics
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)